Astria Therapeutics, Inc.
ATXS
$5.72
$0.122.14%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 35.69M | 34.78M | 32.54M | 30.94M | 28.85M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 124.40M | 111.56M | 100.97M | 92.19M | 78.49M |
Operating Income | -124.40M | -111.56M | -100.97M | -92.19M | -78.49M |
Income Before Tax | -108.04M | -94.26M | -100.04M | -93.24M | -81.63M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -108.04 | -94.26 | -100.04 | -93.24 | -81.63 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -108.04M | -94.26M | -100.04M | -93.24M | -81.63M |
EBIT | -124.40M | -111.56M | -100.97M | -92.19M | -78.49M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -1.88 | -1.68 | -2.09 | -2.30 | -2.32 |
Normalized Basic EPS | -1.17 | -1.05 | -1.05 | -1.18 | -1.19 |
EPS Diluted | -1.88 | -1.68 | -2.09 | -2.30 | -2.32 |
Normalized Diluted EPS | -1.17 | -1.05 | -1.05 | -1.18 | -1.19 |
Average Basic Shares Outstanding | 230.33M | 224.62M | 203.09M | 173.31M | 144.84M |
Average Diluted Shares Outstanding | 230.33M | 224.62M | 203.09M | 173.31M | 144.84M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |